$TYRA
Tyra Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123346 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.907M
YoY Change
% of Gross Profit
Research & Development $22.70M
YoY Change 17.78%
% of Gross Profit
Depreciation & Amortization $100.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $28.60M
YoY Change 19.37%
Operating Profit -$28.60M
YoY Change 19.37%
Interest Expense $4.588M
YoY Change 62.7%
% of Operating Profit
Other Income/Expense, Net $4.588M
YoY Change 63.22%
Pretax Income -$24.02M
YoY Change 13.55%
Income Tax
% Of Pretax Income
Net Earnings -$24.02M
YoY Change 13.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$0.41
COMMON SHARES
Basic Shares Outstanding 50.60M 52.81M
Diluted Shares Outstanding 58.87M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $360.1M
YoY Change 66.96%
Cash & Equivalents $103.9M
Short-Term Investments $256.2M
Other Short-Term Assets $5.481M
YoY Change -39.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $365.6M
YoY Change 62.76%
LONG-TERM ASSETS
Property, Plant & Equipment $1.789M
YoY Change 55.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.006M
YoY Change 12.37%
Total Long-Term Assets $14.98M
YoY Change 9.13%
TOTAL ASSETS
Total Short-Term Assets $365.6M
Total Long-Term Assets $14.98M
Total Assets $380.6M
YoY Change 59.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.165M
YoY Change -49.52%
Accrued Expenses $11.21M
YoY Change 43.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.37M
YoY Change 21.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $11.00K
YoY Change -85.71%
Total Long-Term Liabilities $11.00K
YoY Change -85.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.37M
Total Long-Term Liabilities $11.00K
Total Liabilities $18.30M
YoY Change 13.07%
SHAREHOLDERS EQUITY
Retained Earnings -$225.7M
YoY Change 58.97%
Common Stock $586.3M
YoY Change 60.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $362.3M
YoY Change
Total Liabilities & Shareholders Equity $380.6M
YoY Change 59.67%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$24.02M
YoY Change 13.54%
Depreciation, Depletion And Amortization $100.0K
YoY Change 0.0%
Cash From Operating Activities -$17.90M
YoY Change 4.36%
INVESTING ACTIVITIES
Capital Expenditures $52.00K
YoY Change -42.22%
Acquisitions
YoY Change
Other Investing Activities $21.61M
YoY Change
Cash From Investing Activities $21.56M
YoY Change -24052.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 743.0K
YoY Change 61.52%
NET CHANGE
Cash From Operating Activities -17.90M
Cash From Investing Activities 21.56M
Cash From Financing Activities 743.0K
Net Change In Cash 4.402M
YoY Change -126.23%
FREE CASH FLOW
Cash From Operating Activities -$17.90M
Capital Expenditures $52.00K
Free Cash Flow -$17.95M
YoY Change 4.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001863127
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40800
dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
728-4760
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50602991
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103892000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58006000
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
256238000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
145463000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5481000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8202000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
365611000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
211671000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1789000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2024Q3 tyra Right Of Use Asset
RightOfUseAsset
6186000
CY2023Q4 tyra Right Of Use Asset
RightOfUseAsset
6526000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6006000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5032000
CY2024Q3 us-gaap Assets
Assets
380592000
CY2023Q4 us-gaap Assets
Assets
225857000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4662000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
398000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
280000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10810000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12373000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15333000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5920000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6216000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46000
CY2024Q3 us-gaap Liabilities
Liabilities
18304000
CY2023Q4 us-gaap Liabilities
Liabilities
21595000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52889090
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43099055
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52871825
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43024634
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
586271000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368707000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1752000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
381000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225740000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164830000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
362288000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
380592000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225857000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22697000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19271000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57897000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41841000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5907000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4692000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16536000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12470000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
28604000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
23963000
us-gaap Operating Expenses
OperatingExpenses
74433000
us-gaap Operating Expenses
OperatingExpenses
54311000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28604000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23963000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74433000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54311000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
4588000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
2811000
us-gaap Interest And Other Income
InterestAndOtherIncome
13523000
us-gaap Interest And Other Income
InterestAndOtherIncome
8007000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4588000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2811000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13523000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8007000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24016000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
us-gaap Net Income Loss
NetIncomeLoss
-60910000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1936000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1371000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22080000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21152000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59539000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46304000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58874497
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58874497
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42868340
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42868340
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56599050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56599050
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42619075
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42619075
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
376000
CY2023Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
32000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2433000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
248790000
CY2023Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
494000
CY2023Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
31000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13272000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
238572000
CY2023Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
343000
CY2023Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
30000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4377000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
222170000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2024Q1 tyra Issuance Of Pre Funded Warrants Under Private Placement
IssuanceOfPreFundedWarrantsUnderPrivatePlacement
79022000
CY2024Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
484000
CY2024Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
17000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4115000
CY2024Q1 tyra Available For Sale Debt Securities Net Unerealized Loss
AvailableForSaleDebtSecuritiesNetUnerealizedLoss
-387000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18192000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
389879000
CY2024Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
624000
CY2024Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
9000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4411000
CY2024Q2 tyra Available For Sale Debt Securities Net Unerealized Loss
AvailableForSaleDebtSecuritiesNetUnerealizedLoss
-178000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
376043000
CY2024Q3 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
743000
CY2024Q3 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
9000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7573000
CY2024Q3 tyra Available For Sale Debt Securities Net Unrealized Gain
AvailableForSaleDebtSecuritiesNetUnrealizedGain
1936000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24016000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
362288000
us-gaap Net Income Loss
NetIncomeLoss
-60910000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
375000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
255000
us-gaap Share Based Compensation
ShareBasedCompensation
16099000
us-gaap Share Based Compensation
ShareBasedCompensation
9339000
tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
-4701000
tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
0
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1744000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3910000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2952000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4293000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
161000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-280000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50184000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36607000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
225588000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
120885000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
658000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
167000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105361000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-167000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
1851000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
1213000
tyra Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
200000000
tyra Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
0
tyra Payments Of Issuance Costs For Common Stock And Pre Funded Warrants From Private Placement
PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
420000
tyra Payments Of Issuance Costs For Common Stock And Pre Funded Warrants From Private Placement
PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201431000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1213000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45886000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35561000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59006000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104892000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216652000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103892000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215652000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104892000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216652000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4004000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
146000
tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
35000
tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
93000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
1000000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1000000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
254486000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1753000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
1000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
256238000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145082000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
384000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
145463000
CY2024Q3 tyra Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
2998000
CY2024Q3 tyra Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss
1000
CY2024Q3 tyra Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Greater Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue
0
CY2024Q3 tyra Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss
0
us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
2998000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000
CY2023Q4 tyra Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
9939000
CY2023Q4 tyra Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss
3000
CY2023Q4 tyra Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Greater Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue
0
CY2023Q4 tyra Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss
0
CY2023 us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
9939000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1
CY2024Q3 tyra Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
3000000
CY2024Q3 tyra Accrued Interest Available For Sale Securities
AccruedInterestAvailableForSaleSecurities
1900000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2968000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2435000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1179000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
807000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1789000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2024Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
400000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3787000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5117000
CY2024Q3 tyra Accrued Research And Development
AccruedResearchAndDevelopment
6331000
CY2023Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
4848000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
196000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
132000
CY2024Q3 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
496000
CY2023Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
294000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10810000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2024Q3 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
10751083
CY2023Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
8276442
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21252314
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13083154
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276442
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.07
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40420000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2926848
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.62
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
434818
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17389
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.26
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10751083
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
110998000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4510940
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.7
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
62669000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10751083
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
110998000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7573000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4377000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16099000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9339000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
2000000
CY2024Q3 tyra Accelerate Expense Or Compensation Cost Expense Recognized Due To Termination
AccelerateExpenseOrCompensationCostExpenseRecognizedDueToTermination
1200000
CY2024Q3 tyra Stock Compensation Expense Related To Modification Of Options
StockCompensationExpenseRelatedToModificationOfOptions
800000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
71700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
tyra Purchase Of Common Stock Through Payroll Deduction
PurchaseOfCommonStockThroughPayrollDeduction
0.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85
CY2024Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
200000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
400000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24016000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-21152000
us-gaap Net Income Loss
NetIncomeLoss
-60910000
us-gaap Net Income Loss
NetIncomeLoss
-46304000
CY2024Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
58898277
CY2023Q3 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
43020965
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
56638732
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42822677
CY2024Q3 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
0
CY2023Q3 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-2107
tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
0
tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-2762
CY2024Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-23780
CY2023Q3 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-150518
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-39682
tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-200840
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58874497
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58874497
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42868340
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42868340
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56599050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56599050
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42619075
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42619075
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10769905
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8240944
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
240000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
227000
us-gaap Operating Lease Cost
OperatingLeaseCost
718000
us-gaap Operating Lease Cost
OperatingLeaseCost
473000
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
21000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
69000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
32000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
19000
us-gaap Variable Lease Cost
VariableLeaseCost
95000
us-gaap Variable Lease Cost
VariableLeaseCost
53000
CY2024Q3 us-gaap Lease Cost
LeaseCost
293000
CY2023Q3 us-gaap Lease Cost
LeaseCost
265000
us-gaap Lease Cost
LeaseCost
882000
us-gaap Lease Cost
LeaseCost
565000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
216000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
874000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
900000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
927000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
955000
CY2024Q3 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5032000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8904000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2586000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6318000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
398000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5920000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 tyra Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 tyra Non Rule10 B51 Arr Modified
NonRule10B51ArrModified
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123346-index-headers.html Edgar Link pending
0000950170-24-123346-index.html Edgar Link pending
0000950170-24-123346.txt Edgar Link pending
0000950170-24-123346-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20240930.htm Edgar Link pending
tyra-20240930.xsd Edgar Link pending
tyra-ex10_1.htm Edgar Link pending
tyra-ex10_2.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
tyra-20240930_htm.xml Edgar Link completed